Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Piazza F, Manni S, Ruzzene M, Pinna LA, Gurrieri C, Semenzato G . Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways. Leukemia 2012; 26: 1174–1179.

    Article  CAS  PubMed  Google Scholar 

  2. Trembley JH, Wang G, Unger G, Slaton J, Ahmed K . Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci 2009; 66: 1858–1867.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Martins LR, Lúcio P, Silva MC, Anderes KL, Gameiro P, Silva MG et al. Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia. Blood 2010; 116: 2724–2731.

    Article  CAS  PubMed  Google Scholar 

  4. Kim JS, Eom JI, Cheong JW, Choi AJ, Lee JK, Yang WI et al. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin Cancer Res 2007; 13: 1019–1028.

    Article  CAS  PubMed  Google Scholar 

  5. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008; 118: 3762–3774.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Piazza FA, Ruzzene M, Gurrieri C, Montini B, Bonanni L, Chioetto G et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 2006; 108: 1698–1707.

    Article  CAS  PubMed  Google Scholar 

  7. Ruzzene M, Pinna LA . Addiction to protein kinase CK2: a common denominator of diverse cancer cells? Biochim Biophys Acta 2010; 1804: 499–504.

    Article  CAS  PubMed  Google Scholar 

  8. Martins LR, Lúcio P, Silva MC, Gameiro P, Silva MG, Barata JT et al. On CK2 regulation of chronic lymphocytic leukemia cell viability. Mol Cell Biochem 2011; 356: 51–55.

    Article  CAS  PubMed  Google Scholar 

  9. Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 2010; 70: 10288–10298.

    Article  CAS  PubMed  Google Scholar 

  10. Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE et al. CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy. Mol Cancer Ther 2012; 11: 994–1005.

    Article  CAS  PubMed  Google Scholar 

  11. Marschke RF, Borad MJ, McFarland RW, Alvarez RH, Lim JK, Padgett CS et al. Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2. J Clin Oncol (suppl; abstract 3087) 2011; 29.

  12. Burger JA . Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2011; 2011: 96–103.

    Article  PubMed  Google Scholar 

  13. Choi MY, Kipps TJ . Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J 2012; 18: 404–410.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Martins LR, Paulo L, Melao A, Cardoso BA, Stansfield R, Drygin D et al. In vitro and in vivo targeting of chronic lymphocytic leukemia using CX-4945, a clinical-stage CK2-specific inhibitor. ASH Annual Meeting Abstracts 2012; 120: 2897.

    Google Scholar 

  15. Chou T-C . Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621–681.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S E Spurgeon.

Ethics declarations

Competing interests

BJD is a paid consultant for Cylene Pharmaceuticals, who provided CX-4945 for the work described herein. The remaining authors have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prins, R., Burke, R., Tyner, J. et al. CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. Leukemia 27, 2094–2096 (2013). https://doi.org/10.1038/leu.2013.228

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2013.228

This article is cited by

Search

Quick links